News FDA hands another rejection to Replimune's melanoma therapy Replimune has had its advanced melanoma treatment RP1 turned down by the FDA for a second time, prompting job losses.
News Senju launches first-in-class dry eye disease drug in Japan Senju has launched a new drug for dry eye disease (DED) in Japan, Avarept, the first drug in the TRPV1 antagonist class to reach the market.
News Diagnostics lag is holding back new therapies, says study Advances in therapeutics are outpacing the development of diagnostics due to policy and payment barriers, holding back effective, targeted care.
News Chinese trial backs base-editing drug for thalassaemia A landmark study in China has shown that a base-editing therapy developed by CorrectSequence achieved stellar results in beta-thalassaemia.
News Roche places a $1bn bet on C4T degrader-antibody conjugates Roche is paying $20 million upfront to secure rights to two degrader-antibody conjugates (DACs) for cancer developed by longtime partner C4T.
News Boehringer transfers schizophrenia DTx selling rights to Cli... Boehringer has altered the terms of its digital therapeutic alliance with Click on schizophrenia app CT-155, taking a more strategic investor role.
News Amazon puts $100m into global health drive Amazon Web Services has committed $100m in AI and cloud technology capacity to support the building of health services for "underserved communities."
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
